Brian Adams Sells 6,371 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) insider Brian Adams sold 6,371 shares of Kymera Therapeutics stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $116.83, for a total transaction of $744,323.93. Following the transaction, the insider owned 50,254 shares of the company’s stock, valued at $5,871,174.82. The trade was a 11.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kymera Therapeutics Trading Up 0.1%

Kymera Therapeutics stock traded up $0.11 during mid-day trading on Friday, hitting $117.39. The company had a trading volume of 378,565 shares, compared to its average volume of 733,863. The stock’s 50 day moving average price is $113.97 and its two-hundred day moving average price is $94.74. Kymera Therapeutics, Inc. has a 12 month low of $42.22 and a 12 month high of $130.05. The company has a market capitalization of $9.76 billion, a PE ratio of -36.23 and a beta of 1.96.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.09. The firm had revenue of $65.00 million during the quarter, compared to the consensus estimate of $32.78 million. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%.The company’s revenue was up 465.2% on a year-over-year basis. During the same period last year, the company earned ($0.95) earnings per share. Equities research analysts anticipate that Kymera Therapeutics, Inc. will post -3.78 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Barclays upped their target price on shares of Kymera Therapeutics from $133.00 to $139.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. BTIG Research restated a “buy” rating and issued a $134.00 price objective on shares of Kymera Therapeutics in a report on Thursday, June 25th. Citigroup reaffirmed a “buy” rating on shares of Kymera Therapeutics in a research report on Thursday, August 6th. Deutsche Bank Aktiengesellschaft started coverage on Kymera Therapeutics in a report on Thursday, July 30th. They issued a “hold” rating and a $120.00 target price for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $128.70.

Institutional Trading of Kymera Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Allianz Asset Management GmbH purchased a new stake in shares of Kymera Therapeutics during the 2nd quarter valued at about $516,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Kymera Therapeutics in the 2nd quarter worth $344,000. California State Teachers Retirement System raised its holdings in Kymera Therapeutics by 10,989.5% in the 2nd quarter. California State Teachers Retirement System now owns 6,241,373 shares of the company’s stock worth $715,698,000 after purchasing an additional 6,185,091 shares during the period. DMC Group LLC bought a new position in Kymera Therapeutics in the 2nd quarter worth $229,000. Finally, Braidwell LP lifted its position in Kymera Therapeutics by 12.0% during the second quarter. Braidwell LP now owns 378,163 shares of the company’s stock valued at $43,364,000 after purchasing an additional 40,604 shares in the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.